DGAP-News

PAION AG: RECRUITMENT OF PHASE II/III STUDY WITH SHORT-ACTING ANAESTHETIC/SEDATIVE REMIMAZOLAM (ONO'S DEVELOPMENT CODE: ONO-2745) IN JAPAN IS COMPLETED

DGAP-News: PAION AG / Key word(s): Research Update
PAION AG: RECRUITMENT OF PHASE II/III STUDY WITH SHORT-ACTING
ANAESTHETIC/SEDATIVE REMIMAZOLAM (ONO'S DEVELOPMENT CODE: ONO-2745) IN
JAPAN IS COMPLETED

08.05.2013 / 11:06

---------------------------------------------------------------------

RECRUITMENT OF PHASE II/III STUDY WITH SHORT-ACTING ANAESTHETIC/SEDATIVE
REMIMAZOLAM (ONO'S DEVELOPMENT CODE: ONO-2745) IN JAPAN IS COMPLETED

Aachen (Germany), 08 May 2013 - The biopharmaceutical company PAION AG
(ISIN DE000A0B65S3; Frankfurt Stock Exchange, General Standard: PA8) today
announces that its partner, Ono Pharmaceutical Co., Ltd. ('ONO') has
published, that the recruitment of the Phase II/III study with Remimazolam
for general anaesthesia is completed. Remimazolam was administered during
anaesthesia to 375 surgery patients.

The objective of this study was to investigate efficacy and safety of
Remimazolam in induction and maintenance of general anaesthesia in a
multicenter randomized parallel-group study compared to propofol in surgery
patients requiring general anaesthesia.

ONO entered into the license agreement with PAION UK Ltd. (former CeNeS
Limited) in 2007 to develop and commercialize Remimazolam in Japan and is
developing the substance for the Japanese market for both 'induction and
maintenance of anaesthesia' and 'ICU sedation'.

'Again Ono has beaten our expectations and we expect that the excellent
efficacy and safety profile seen in the previous studies will be
confirmed', said PAION CEO Dr Wolfgang Söhngen. 'This will add to the
current momentum in the ongoing discussions to fund the development outside
of Japan.'

###

About PAION
PAION AG is a publicly-listed biotech company headquartered in Aachen,
Germany with a second site in Cambridge, UK. The company has a track record
in developing hospital-based treatments for which there is substantial
unmet medical need. PAION AG is transforming its business model from a pure
development company to a specialty pharmaceutical company with a focus on
anaesthesia products to take advantage of the unique profile of its main
compound, Remimazolam.

About Remimazolam
Remimazolam is an innovative short-acting general anaesthetic/sedative. Due
to its short duration of action and good controllability, it has a
preferable efficacy and safety profile relative to other currently marketed
anaesthesia compounds. The rapid offset of Remimazolam's effect is due to
its metabolism by tissue esterase enzymes that are widely distributed
throughout the body.

Remimazolam has potential in three indications: